Stephen John Hoffman
Physician at Albion St, Denver, CO
License number
Colorado 28443
Issued Date
Oct 8, 1987
Renew Date
May 31, 1995
Expiration Date
May 31, 1995
Type
Physician
Address
Address
2090 Albion St, Denver, CO 80207
Personal information
See more information about Stephen John Hoffman at radaris.comName
Address
Phone
5335 Garland St, Arvada, CO 80002
3845 Lakehurst Dr, Colorado Springs, CO 80916
433 La Bonte, Dillon, CO 80435
Professional information
Stephen Hoffman - Denver, CO
Work:
Horizon Property Services LLC
Building Engineer Denver Athletic Club - Denver, CO
Building Engineer Stewart Boyer - Denver, CO
Controls Installer C.B.R.E - Denver, CO
Maintenance Technician Highlands Ranch Learning Center - Highlands Ranch, CO
maintenance Trammel Crow - Greenwood Village, CO
Building Engineer Jones Lang LaSalle - Greenwood Village, CO
Day Porter
Building Engineer Denver Athletic Club - Denver, CO
Building Engineer Stewart Boyer - Denver, CO
Controls Installer C.B.R.E - Denver, CO
Maintenance Technician Highlands Ranch Learning Center - Highlands Ranch, CO
maintenance Trammel Crow - Greenwood Village, CO
Building Engineer Jones Lang LaSalle - Greenwood Village, CO
Day Porter
Education:
Emily Griffith School of Opportunity - Denver, CO
Air Conditioning and Heating
Air Conditioning and Heating
Dna Encoding Fused Di-Alpha Globins And Use Thereof
US Patent:
6828125, Dec 7, 2004
Filed:
May 30, 1995
Appl. No.:
08/453485
Inventors:
Stephen J. Hoffman - Denver CO
Douglas L. Looker - Lafayette CO
Kiyoshi Nagai - Cambridge, GB
Douglas L. Looker - Lafayette CO
Kiyoshi Nagai - Cambridge, GB
Assignee:
Baxter Biotech Technology, S.a.r.l. - Neuchatel
International Classification:
C12P 2106
US Classification:
435 696, 435 691, 4353201, 536 231, 530385
Abstract:
The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
Co-Expression Of Alpha And Beta Globins
US Patent:
5798227, Aug 25, 1998
Filed:
May 19, 1995
Appl. No.:
8/446105
Inventors:
Stephen J. Hoffman - Denver CO
Douglas L. Looker - Lafayette CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
Douglas L. Looker - Lafayette CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C12P 2106, C12P 2104, C12N 120, C07K 14805
US Classification:
435 696
Abstract:
The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
We further describe the production of tetrameric human hemoglobin and di-alpha/beta. sub. 2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site. The expression construct is designed such that translation is expected to initiate at the same position as the human wild-type genes for. alpha. - and. beta. -globin.
Hemoglobin-Like Protein Comprising Genetically Fused Globin-Like Polypeptides
US Patent:
5844088, Dec 1, 1998
Filed:
May 19, 1995
Appl. No.:
8/444991
Inventors:
Stephen J. Hoffman - Denver CO
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C07K 14805
US Classification:
530385
Abstract:
The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
We further describe the production of tetrameric human hemoglobin and di-alpha/beta. sub. 2 hemoglobin in the yeast Saccharomyces cerevisiae. The synthesis of the protein is directed by a synthetic promotor consisting of two functional parts, an upstream activator sequence (UAS) that confers inducible transcription by galactose from a consensus yeast transcriptional initiation site. The expression construct is designed such that translation is expected to initiate at the same position as the human wild-type genes for. alpha. - and. beta. -globin.
Hemoglobins With Intersubunit Disulfide Bonds
US Patent:
5776890, Jul 7, 1998
Filed:
May 30, 1995
Appl. No.:
8/453666
Inventors:
Stephen J. Hoffman - Denver CO
Kiyoshi Nagai - Cambridge, GB2
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C07K 14805
US Classification:
514 6
Abstract:
Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes. Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen. Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".
Hemoglobins With Intersubunit Desulfide Bonds
US Patent:
5449759, Sep 12, 1995
Filed:
Nov 29, 1993
Appl. No.:
8/158483
Inventors:
Stephen J. Hoffman - Denver CO
Kiyoshi Nagai - Cambridge, GB2
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C07K 14805, A61K 3842
US Classification:
530385
Abstract:
Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes.
Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen.
Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".
Genetically Fused Globin-Like Polypeptides Having Hemoglobin-Like Activity
US Patent:
5844089, Dec 1, 1998
Filed:
May 25, 1995
Appl. No.:
8/450733
Inventors:
Stephen J. Hoffman - Denver CO
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C07K 14805
US Classification:
530385
Abstract:
The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
Dna Encoding Fused Di-Beta Globins And Production Of Pseudotetrameric Hemoglobin
US Patent:
5744329, Apr 28, 1998
Filed:
May 19, 1995
Appl. No.:
8/444942
Inventors:
Stephen J. Hoffman - Denver CO
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Douglas L. Looker - Lafayette CO
Mary S. Rosendahl - Broomfield CO
Gary L. Stetler - Denver CO
Michael Wagenbach - Osaka, JP
David C. Anderson - Lafayette CO
Antony James Mathews - Louisville CO
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
C12P 2106, C07H 1700, C07K 14805
US Classification:
435696
Abstract:
The alpha subunits of hemoglobin, which in nature are formed as separate polypeptide chains which bind noncovalently to the beta subunits, are here provided in the form of the novel molecule di-alpha globin, a single polypeptide chain defined by connecting the two alpha subunits either directly via peptide bond or indirectly by a flexible amino acid or peptide linker. Di-alpha globin may be combined in vivo or in vitro with beta globin and heme to form hemoglobin. Di-alpha globin is expressed by recombinant DNA techniques. Di-beta globin may be similarly obtained.
Blood Substitutes
US Patent:
5028588, Jul 2, 1991
Filed:
May 16, 1988
Appl. No.:
7/194338
Inventors:
Stephen L. Hoffman - Denver CO
Kiyoshi Nagai - Cambridge, GB2
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogenetics International, Inc. - Broomfield CO
International Classification:
A61K 3714, C07K 1300
US Classification:
514 6
Abstract:
Solutions of mutant hemoglobins having a lower oxygen affinity than that of native hemoglobin are used as blood substitutes. The mutant hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be so prepared, making possible the production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes.
Blood Substitutes
US Patent:
5661124, Aug 26, 1997
Filed:
Mar 1, 1995
Appl. No.:
8/396866
Inventors:
Stephen J. Hoffman - Denver CO
Kiyoshi Nagai - Cambridge, GB2
Kiyoshi Nagai - Cambridge, GB2
Assignee:
Somatogen, Inc. - Boulder CO
International Classification:
A61K 3816, C07K 1400
US Classification:
514 6
Abstract:
The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally comprises a physiologically acceptable molecule less diffusible than dextrose.